CIPLA.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 May 2024 @ 05:59):

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally...

Stats
Today's Volume	7.91M
Average Volume	1.58M
Market Cap	1 142.18B
EPS	INR0 ( 2024-05-09 )
Next earnings date	( INR10.73 ) 2024-07-24
Last Dividend	INR8.50 ( 2023-07-20 )
Next Dividend	INR0 ( N/A )
P/E	27.72
ATR14	INR1.395 (0.10%)

Volume Correlation

Long: -0.06 (neutral)

Short: 0.02 (neutral)

Signal:(74.884) Neutral

Cipla Limited Correlation

10 Most Positive Correlations
NESCO.NS	0.972
SPENTEX.NS	0.97
PODDARHOUS.NS	0.967
HONAUT.NS	0.965
INSECTICID.NS	0.963
SHAILY.NS	0.962
JINDALPOLY.NS	0.96
AWHCL.NS	0.957
ESTER.NS	0.957
SETUINFRA.NS	0.957

10 Most Negative Correlations
KIRLFER.NS	-0.948
JSLHISAR.NS	-0.937
CIGNITITEC.NS	-0.933
JINDALSAW.NS	-0.931
PGEL.NS	-0.925
SONATSOFTW.NS	-0.919
KAYNES.NS	-0.918
OIL.NS	-0.918
ISMTLTD.NS	-0.917
CLSEL.NS	-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cipla Limited Correlation - Currency/Commodity

-0.28
( neutral )

-0.55
( weak negative )

0.48
( neutral )

-0.10
( neutral )

-0.49
( neutral )

Cipla Limited Financials

Annual	2023
Revenue:	INR257.74B
Gross Profit:	INR115.93B (44.98 %)
EPS:	INR51.05

FY	2023
Revenue:	INR257.74B
Gross Profit:	INR115.93B (44.98 %)
EPS:	INR51.05

FY	2022
Revenue:	INR224.73B
Gross Profit:	INR142.21B (63.28 %)
EPS:	INR34.72

FY	2022
Revenue:	INR216.33B
Gross Profit:	INR124.03B (57.33 %)
EPS:	INR31.20

Financial Reports:

No articles found.

Cipla Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR8.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Cipla Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.05 - Decrease likely (38.96%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0933	1997-07-28
Last Dividend	INR8.50	2023-07-20
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	28	--
Total Paid Out	INR55.50	--
Avg. Dividend % Per Year	0.41%	--
Score	2.92	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.05
Div. Directional Score	6.59	--

Next Divdend (Est)
(2024-07-01)

INR9.30 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.92

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.00	0.51%
2019	INR3.00	0.57%
2020	INR1.000	0.21%
2021	INR5.00	0.61%
2022	INR5.00	0.54%
2023	INR8.50	0.79%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SSWL.NS	Dividend Junior	2023-08-14	Annually	20	0.30%
MRF.NS	Dividend Knight	2023-07-20	Semi-Annually	23	0.11%
HEROMOTOCO.NS	Dividend Knight	2023-07-27	Semi-Annually	22	2.06%
BIOCON.NS	Dividend Junior	2023-07-06	Sporadic	21	0.18%
RECLTD.NS	Dividend King	2023-08-14	Quarterly	17	6.82%
KOTHARIPET.NS	Dividend Junior	2023-08-02	Annually	14	0.47%
ESTER.NS	Dividend Junior	2023-09-20	Sporadic	14	1.55%
ALPHAGEO.NS	Dividend Junior	2023-09-22	Annually	18	2.07%
TASTYBITE.NS	Dividend Junior	2023-07-14	Annually	8	0.01%
NGIL.NS	No Dividend Player	2023-09-21	Annually	4	0.08%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.161	1.500	6.77	10.00	[0 - 0.5]
returnOnAssetsTTM	0.126	1.200	5.80	6.96	[0 - 0.3]
returnOnEquityTTM	0.164	1.500	9.29	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.70	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.993	0.800	2.98	2.39	[0.8 - 2.5]
cashRatioTTM	0.167	1.500	-0.184	-0.277	[0.2 - 2]
debtRatioTTM	0.0102	-1.500	9.83	-10.00	[0 - 0.6]
interestCoverageTTM	62.32	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	19.38	2.00	3.54	7.08	[0 - 30]
freeCashFlowPerShareTTM	19.38	2.00	0.311	0.622	[0 - 20]
debtEquityRatioTTM	0.0125	-1.500	9.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.601	1.000	3.32	3.32	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.68	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.780	0.800	8.13	6.51	[0.5 - 2]
Total Score				10.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	27.47	1.000	7.33	0	[1 - 100]
returnOnEquityTTM	0.164	2.50	9.54	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.38	2.00	3.54	0.622	[0 - 30]
dividendYielPercentageTTM	0.606	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	19.38	2.00	3.54	7.08	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.73	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0613	1.000	-0.968	0	[0.1 - 0.5]
Total Score				3.05

Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.